Background: Endometrial cancer is the most frequent ontological pathology in postmenopausal disassociated with abnormal uterine bleeding. Different studies have found a significant relationship between increased endometrial thickness and the risk of EC. Objectives: We aimed to study an endometrial cancer clinical presentation, factor and the type of endometrial cancer in relation to the endometrial thickness, in tumor therapy and cancer research center (TTCRC) in Shendi city. Methodology: This is a descriptive cross-sectional Hospital–based study including 120 Sudanese women attend the (TTCRC), the data were collected by questionnaire from histopathology laboratory and medical statistical department. Results: The mean age of our participants was 57.9± years. Multi 78 porous was observed in 64 cases (53.3%), Obesity (≥30–39.9BMI) in 43cases (35.8%), just12cases (10%) had family history with EC, and post-menopausal bleeding in 47 cases (39.5%). There were 68 cases (56.7%) of Aden carcinoma (with squamous differentiation) and 40 cases (33.3%) their endometrial thickness 4-10 mm. There were significant association between endometrial thickness and, type EC (all P<0.05), and significant with age and clinical presentation (P=0.027). Conclusion: the in cadence of EC in the patients was higher in age <50 years, Multi-parous, BMI ≥ 30kg/m2, PMB was higher ate clinical presentation, Aden carcinoma (with squamous differentiation were common type of EC, most of the cases the in endometrial thickness were 4-10 mm and we found significant association with Type EC.
Published in | Journal of Cancer Treatment and Research (Volume 11, Issue 4) |
DOI | 10.11648/j.jctr.20231104.11 |
Page(s) | 38-45 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Endometrial Cancer, Shendi, Sudan
[1] | Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019; 144 (8): 1941–1953. doi: 10.1002/ijc.31937. |
[2] | Lortet-Tieulent J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst 2017; 110: 354–361. |
[3] | Mukhopadhaya N, Manyonda IT. The hysterectomy story in the United Kingdom. J Midlife Health 2013; 4: 40–1. |
[4] | Norris HI, Tavassoli FA, Kurman RJ: Endometrial hyperplasia and carcinoma: Diagnostic considerations. Am J Surg Pathol 7: 839–847, 1983. |
[5] | Ross JC, Kempson RL: To ward the development of morphologic criteria for well differentiated adenocarcinoma of the endometrium. Am J Surg Pathol 7: 819–838, 1983. |
[6] | Davies JL, Rosenshein NB, Antunes CMF, Stolley PD: Areview of the risk factors for endometrial cancer. Obstet Gynecol Surv 36: 107–116, 1981. |
[7] | Smith M, McCartney J: Occult high-risk endometrial cancer. Gynecol Oncol 22: 154–161, 1985. |
[8] | Brinton LA, Hoover RN: The endometrial cancer collaborative group: Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. ObstetGynecol81: 265–271, 1993. |
[9] | Koss LG, Scheiber K, Oberlander S et al: Detection of endometrial carcinoma and hyperplasia in asymptomatic cwomen. Obstet Gynecol64: 1–11, 1984. |
[10] | Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 921–9. |
[11] | Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., Ezzati, M., 2018. World wide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinal. 6 (2), 95–104. |
[12] | Kim, M., Kim, J., Kim, S., 2016. Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women. Obstet. Gynecol. Sci. 59 (3), 192–200. |
[13] | Schramm, A., Ebner, F., Bauer, E., Janni, W., Friebe-Hoffmann, U., Pellegrino, M., De Gregorio, N., Friedl, T. W. P., 2017. Value of endometrial thickness assessed by transvaginal ultrasound for the prediction of endometrial cancer in patients with postmenopausal bleeding. Arch. Gynecol. Obstet. 296 (2), 319–326. |
[14] | Wong, A. S., Cheung, C. W., Fung, L. W., Lao, T. T., Mol, B. W., Sahota, D. S., 2016a. Development and validation of prediction models for endometrial cancer in postmenopausal bleeding. Eur. J. Obstet. Gynecol. Reprod. Biol. 203, 220–224. |
[15] | Wise, M. R., Gill, P., Lensen, S., Thompson, J. M., Farquhar, C. M., 2016. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am. J. Obstet. Gynecol. 2015 (5), 598e1–e8. |
[16] | The American College of Obstetricians and Gynecologists Committee Opinion, 2013. Management of Acute Abnormal Uterine Bleeding in Non-pregnant Reproductive Aged Women. 557. pp. 1–6. |
[17] | Duska L. R., 2017. Recognising endometrial cancer in pre-menopausal women. BJOG 124 (3), 412. |
[18] | Simin, J., Tamimi, R., Lagergren, J., Adami, H. O., Brusselaers, N., 2017. Menopausal hormone therapy and cancer risk: an overestimated risk? Eur. J. Cancer 84, 60–68. |
[19] | MakkerV, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021 Dec 9; 7 (1): 88. DOI: 10.1038/s41572-021-00324-8. PMID: 34887451; PMCID: PMC9421940. |
[20] | ZhouB, Yang L, Sun Q, et al. Cigarette smoking and the risk of endmetrial cancer: a meta-analysis. Am J Med 2018; 121: 501–8. e3. |
[21] | World Cancer Research Fund International/American Institute for Cancer Research continuous update project report. Diet, nutrition, physical activity, and endometrial cancer 2013. |
[22] | Wu QJ, Li YY, Tu C, et al. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep 2015; 5: 14243. |
[23] | Matsuo K, Mandelbaum RS, Ciccone M, et al. Routespecific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. Int J Gynecol Cancer. 2020; 30 (9): 1331–9. |
[24] | Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatter jee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019; 58 (3): 342–52. |
[25] | Bagnoli VR, Fonseca AMD, Massabki JOP, Arie WMY, Azevedo RS, Veiga ECA, Soares Junior JM, Baracat EC. Gynecological cancer and metabolic screening of 1001 elderly Brazilian women. 2019 Nov 7; 65 (10): 1275-1282. DOI: 10.1590/1806-9282.65.10.1275. PMID: 31721959. |
APA Style
Mawahib Mohammad Mohammad Ahmad Al-Tohami, Dr. Motwakil Imam Awadelkareim Imam, Mohamed Alhag Alobed. (2023). Clinical Presentations, Risk Factors and Type of Endometrial Cancer in Relation to Endometrial Thickness in Tumour Therapy and Cancer Research Centre Shendi University. Journal of Cancer Treatment and Research, 11(4), 38-45. https://doi.org/10.11648/j.jctr.20231104.11
ACS Style
Mawahib Mohammad Mohammad Ahmad Al-Tohami; Dr. Motwakil Imam Awadelkareim Imam; Mohamed Alhag Alobed. Clinical Presentations, Risk Factors and Type of Endometrial Cancer in Relation to Endometrial Thickness in Tumour Therapy and Cancer Research Centre Shendi University. J. Cancer Treat. Res. 2023, 11(4), 38-45. doi: 10.11648/j.jctr.20231104.11
AMA Style
Mawahib Mohammad Mohammad Ahmad Al-Tohami, Dr. Motwakil Imam Awadelkareim Imam, Mohamed Alhag Alobed. Clinical Presentations, Risk Factors and Type of Endometrial Cancer in Relation to Endometrial Thickness in Tumour Therapy and Cancer Research Centre Shendi University. J Cancer Treat Res. 2023;11(4):38-45. doi: 10.11648/j.jctr.20231104.11
@article{10.11648/j.jctr.20231104.11, author = {Mawahib Mohammad Mohammad Ahmad Al-Tohami and Dr. Motwakil Imam Awadelkareim Imam and Mohamed Alhag Alobed}, title = {Clinical Presentations, Risk Factors and Type of Endometrial Cancer in Relation to Endometrial Thickness in Tumour Therapy and Cancer Research Centre Shendi University}, journal = {Journal of Cancer Treatment and Research}, volume = {11}, number = {4}, pages = {38-45}, doi = {10.11648/j.jctr.20231104.11}, url = {https://doi.org/10.11648/j.jctr.20231104.11}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20231104.11}, abstract = {Background: Endometrial cancer is the most frequent ontological pathology in postmenopausal disassociated with abnormal uterine bleeding. Different studies have found a significant relationship between increased endometrial thickness and the risk of EC. Objectives: We aimed to study an endometrial cancer clinical presentation, factor and the type of endometrial cancer in relation to the endometrial thickness, in tumor therapy and cancer research center (TTCRC) in Shendi city. Methodology: This is a descriptive cross-sectional Hospital–based study including 120 Sudanese women attend the (TTCRC), the data were collected by questionnaire from histopathology laboratory and medical statistical department. Results: The mean age of our participants was 57.9± years. Multi 78 porous was observed in 64 cases (53.3%), Obesity (≥30–39.9BMI) in 43cases (35.8%), just12cases (10%) had family history with EC, and post-menopausal bleeding in 47 cases (39.5%). There were 68 cases (56.7%) of Aden carcinoma (with squamous differentiation) and 40 cases (33.3%) their endometrial thickness 4-10 mm. There were significant association between endometrial thickness and, type EC (all PConclusion: the in cadence of EC in the patients was higher in age <50 years, Multi-parous, BMI ≥ 30kg/m2, PMB was higher ate clinical presentation, Aden carcinoma (with squamous differentiation were common type of EC, most of the cases the in endometrial thickness were 4-10 mm and we found significant association with Type EC. }, year = {2023} }
TY - JOUR T1 - Clinical Presentations, Risk Factors and Type of Endometrial Cancer in Relation to Endometrial Thickness in Tumour Therapy and Cancer Research Centre Shendi University AU - Mawahib Mohammad Mohammad Ahmad Al-Tohami AU - Dr. Motwakil Imam Awadelkareim Imam AU - Mohamed Alhag Alobed Y1 - 2023/10/28 PY - 2023 N1 - https://doi.org/10.11648/j.jctr.20231104.11 DO - 10.11648/j.jctr.20231104.11 T2 - Journal of Cancer Treatment and Research JF - Journal of Cancer Treatment and Research JO - Journal of Cancer Treatment and Research SP - 38 EP - 45 PB - Science Publishing Group SN - 2376-7790 UR - https://doi.org/10.11648/j.jctr.20231104.11 AB - Background: Endometrial cancer is the most frequent ontological pathology in postmenopausal disassociated with abnormal uterine bleeding. Different studies have found a significant relationship between increased endometrial thickness and the risk of EC. Objectives: We aimed to study an endometrial cancer clinical presentation, factor and the type of endometrial cancer in relation to the endometrial thickness, in tumor therapy and cancer research center (TTCRC) in Shendi city. Methodology: This is a descriptive cross-sectional Hospital–based study including 120 Sudanese women attend the (TTCRC), the data were collected by questionnaire from histopathology laboratory and medical statistical department. Results: The mean age of our participants was 57.9± years. Multi 78 porous was observed in 64 cases (53.3%), Obesity (≥30–39.9BMI) in 43cases (35.8%), just12cases (10%) had family history with EC, and post-menopausal bleeding in 47 cases (39.5%). There were 68 cases (56.7%) of Aden carcinoma (with squamous differentiation) and 40 cases (33.3%) their endometrial thickness 4-10 mm. There were significant association between endometrial thickness and, type EC (all PConclusion: the in cadence of EC in the patients was higher in age <50 years, Multi-parous, BMI ≥ 30kg/m2, PMB was higher ate clinical presentation, Aden carcinoma (with squamous differentiation were common type of EC, most of the cases the in endometrial thickness were 4-10 mm and we found significant association with Type EC. VL - 11 IS - 4 ER -